Provided herein are genetically engineered recombinant modified vaccinia virus Ankara (MVA) vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein in particular RSV-F and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein including nucleocapsid N protein and/or M2. Specifically, provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.
